She barely traded for three years. Then she bought the dip the day before Trump paused his tariffs.

Marjorie Taylor Greene represented Georgia's 14th congressional district, a deep-red stretch of Northwest Georgia running from the edge of the Chattanooga metro to the exurbs of Atlanta, from January 2021 until she resigned on January 5, 2026. For most of her tenure she was one of the most recognizable figures in the MAGA movement, and by the end of it one of its loudest internal dissidents.

Her pre-politics career was in family business. Taylor Commercial, a commercial construction and renovation firm, was acquired by Greene and her then-husband in 2002, and she was listed as an officer there for years. In 2013 she co-founded a CrossFit gym in Alpharetta, Georgia, which she left in 2017. Public estimates put her net worth between roughly $20 million and $25 million, up from a reported $700,000 or so before she entered Congress. Greene attributes that wealth to her businesses, built well before she ran for office, a point she returns to whenever her trading comes up.

She was first elected in 2020 to the seat vacated by retiring Republican Tom Graves, winning a low-turnout primary runoff and then the general in a district that rarely elects Democrats. She built one of the largest small-dollar fundraising operations in the House almost immediately. What she did not build, for the first three years, was a stock portfolio anyone had reason to watch. That changed in 2024, and the change is the reason this page exists.

Greene spent an unusual share of her career with no committee assignments at all. On February 4, 2021, barely a month into her first term, the full House voted 230 to 199 (eleven Republicans joining every Democrat) to strip her of both of her seats, on the Budget Committee and the Education and Labor Committee, over past social-media activity. She then spent two years with no committee role.

When Republicans retook the House in 2023, the GOP Steering Committee placed her on Oversight and Accountability and on Homeland Security. In the 119th Congress she chaired the Oversight subcommittee on Delivering on Government Efficiency, the congressional companion to the Trump administration's DOGE initiative. After she resigned, that subcommittee did not disappear; Representative Tim Burchett took over as chair.

Here is the part that matters for reading her trades. None of those assignments gave her oversight of the sectors she actually traded. She never sat on Financial Services, Ways and Means, or Energy and Commerce. Her most-scrutinized trades cluster around macro events visible to the entire market (a tariff announcement, a health-insurer collapse), not around a bill moving through a committee she sat on. That makes her profile different from Tommy Tuberville trading defense names while on Armed Services, or the Pelosi household in tech. The standard question we ask about a trade, does the member oversee the sector, mostly returns no for Greene. With her the question is different. It is about timing, and about proximity to the person setting the macro policy.

For her first three years in office Greene was a negligible trader. The one early exception is itself instructive: in late February 2022 her account bought Lockheed Martin and Caterpillar days before Russia invaded Ukraine, and roughly a day before she tweeted criticism of war profiteering. The trades drew a brief news cycle, and then she went quiet again.

The real inflection point was May 2024. After years with essentially no disclosed stock purchases, filings began arriving every month or two, and then nearly every month. In 2024 her account disclosed roughly $3.9 million in stock purchases and finished the year up about 30 percent, ahead of the S&P 500. In 2025 the pace exploded: 216 disclosed trades over the year, at least one filing every month, 161 of them profitable, and 92 of them up 10 percent or more. By the time she left, public trackers like Capitol Trades counted more than 400 trades across her tenure and total disclosed volume near $9 million.

A few caveats belong on those numbers, and they apply to every congressional trader. Disclosures report amount ranges, not exact figures, so a "476 percent gain" and a "$9 million in volume" are reconstructions built on the midpoints and edges of those ranges, not audited returns. Trackers also disagree on the raw trade count depending on how they handle Treasury-bill rollovers and multi-line filings. The direction of the story, though, is unambiguous across every source: a portfolio that sat dormant for three years became one of the most active in Congress almost overnight. Whether that kind of activity produces a real edge is a separate and well-studied question, which we cover in do members of Congress actually beat the market.

Five weeks later, the pattern repeated against a different falling knife. UnitedHealth Group, the largest health insurer in the country, lost roughly half its value in a matter of weeks as a Department of Justice criminal investigation into its Medicare Advantage billing became public, CEO Andrew Witty abruptly stepped down, and the company suspended its guidance. CMS had also just announced an expanded audit of Medicare Advantage overbilling.

On May 14, 2025, Greene's account made its first-ever disclosed UnitedHealth purchase, in the $15,001 to $50,000 range, and added more on May 16. The same mid-May filing included other healthcare names (Cardinal Health, Eli Lilly, Amgen) alongside a broad technology and consumer basket and another large Treasury-bill position. She was buying UnitedHealth in the same window that Warren Buffett's Berkshire Hathaway and investor Michael Burry disclosed stakes, so the trade was not contrarian in isolation.

It is worth being precise about the catalyst, because the easy version of this story overreaches. The documented drivers of the UnitedHealth collapse were the DOJ probe, the CEO exit, and the CMS audit, not a single piece of legislation. The deeper Medicaid story that ran in parallel that spring, the roughly $1 trillion in Medicaid cuts in the One Big Beautiful Bill, is the subject of its own reporting, and Greene appears in it as one of several members who bought health insurers in the same window. We lay out the insurer landscape and that legislative timeline in congress and health insurance stock trades.

The tariff and UnitedHealth trades are the famous ones, but they sit inside a much larger book. By the end of her tenure Greene's account showed more than 400 disclosed transactions across roughly 100 names, heavily tilted toward technology, with consumer discretionary and financials behind it. Her single most-traded line was U.S. Treasury bills, which she used as a cash-management vehicle, frequently rotating $50,000 to $250,000 in and out to fund equity purchases. After T-bills, her most-traded names were Amazon, Tesla, and UPS.

Two features stand out. First, she was overwhelmingly a buyer. Capitol Trades characterized her as effectively buy-and-hold, with just a single equity sale recorded across all of 2025 apart from the Treasury rotations. Second, the winners were concentrated in megacap tech and AI: beyond the Palantir tariff trade, her Tesla position bought near $210 in September 2024 ran up more than 80 percent, and she held AMD and CrowdStrike through strong gains. Late in 2025 she was still adding, including a small iShares Bitcoin Trust position on December 3 and steadier names like Automatic Data Processing, Paychex, and Procter and Gamble in November.

For all the volume, one thing she was not is a late filer. There is no documented STOCK Act violation or fine on her record. Her disclosures were filed inside the 45-day window the law requires (the May 14 UnitedHealth purchase, for instance, was on file by May 19). That is an important distinction. With some members the story is sloppy or late paperwork. With Greene the paperwork was clean. The entire controversy is about the timing and nature of the trades, which is exactly the gap that disclosure law, by design, does nothing to address. We catalog those gaps in the STOCK Act loopholes.

The final irony of Greene's trading story is in the timing of her exit. Through 2025 her trades became the most-cited real-world example in the renewed push to ban congressional stock trading. Both Speaker Mike Johnson and Trump himself voiced support for a ban that year, and a bipartisan group (Anna Paulina Luna, Chip Roy, Brian Fitzpatrick, Alexandria Ocasio-Cortez) pushed legislation forward, while House Democratic leadership maneuvered over a competing version. We score those competing bills in the congressional stock trading ban bills compared, and tell the longer reform story in the congressional stock trading ban explained.

Then the ground shifted under her for reasons that had nothing to do with stocks. In November 2025 Greene broke with Trump publicly, becoming one of only four Republicans to sign the discharge petition forcing a House vote on releasing the Jeffrey Epstein files. She said Trump had told her his "friends will get hurt." The split widened over foreign policy and over her insistence that the party had no answer for rising health-insurance premiums. Trump withdrew his endorsement and called her a "traitor" and a "Lunatic," and signaled he would back a primary challenger. On November 21, 2025, Greene announced she would resign. Her last day was January 5, 2026.

The disclosure trail ends there. A special election sent Republican Clay Fuller, backed by Trump, to finish the term. Greene has since moved into media, including an appearance on ABC's The View two days after leaving office. The member who became the headline argument for a trading ban left Congress before any ban reached the floor, which means the most-watched Republican trading record of the Trump era is now closed, frozen at the moment she walked out. For the broader field of who was trading and how often while she was still in office, see the most active stock traders in Congress.